- Home
- SION vs BME Comparison
SION vs BME Comparison
Compare SION & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SION
- BME
- Stock Information
- Founded
- SION 2019
- BME 2005
- Country
- SION United States
- BME United States
- Employees
- SION N/A
- BME N/A
- Industry
- SION
- BME Trusts Except Educational Religious and Charitable
- Sector
- SION
- BME Finance
- Exchange
- SION NYSE
- BME Nasdaq
- Market Cap
- SION 338.0M
- BME 462.3M
- IPO Year
- SION 2025
- BME N/A
- Fundamental
- Price
- SION $12.14
- BME $36.59
- Analyst Decision
- SION Strong Buy
- BME
- Analyst Count
- SION 1
- BME 0
- Target Price
- SION $32.00
- BME N/A
- AVG Volume (30 Days)
- SION 151.8K
- BME 34.0K
- Earning Date
- SION 05-25-2025
- BME 01-01-0001
- Dividend Yield
- SION N/A
- BME 6.26%
- EPS Growth
- SION N/A
- BME N/A
- EPS
- SION N/A
- BME 1.44
- Revenue
- SION N/A
- BME N/A
- Revenue This Year
- SION N/A
- BME N/A
- Revenue Next Year
- SION N/A
- BME N/A
- P/E Ratio
- SION N/A
- BME $28.37
- Revenue Growth
- SION N/A
- BME N/A
- 52 Week Low
- SION $7.26
- BME $35.53
- 52 Week High
- SION $25.19
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- SION N/A
- BME 46.39
- Support Level
- SION N/A
- BME $36.09
- Resistance Level
- SION N/A
- BME $36.79
- Average True Range (ATR)
- SION 0.00
- BME 1.03
- MACD
- SION 0.00
- BME 0.15
- Stochastic Oscillator
- SION 0.00
- BME 92.34
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.